VASOCIDIN Drug Patent Profile
Which patents cover Vasocidin, and what generic alternatives are available?
Vasocidin is a drug marketed by Novartis and is included in two NDAs.
The generic ingredient in VASOCIDIN is prednisolone sodium phosphate; sulfacetamide sodium. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate; sulfacetamide sodium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VASOCIDIN?
- What are the global sales for VASOCIDIN?
- What is Average Wholesale Price for VASOCIDIN?
Summary for VASOCIDIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 8 |
| DailyMed Link: | VASOCIDIN at DailyMed |
US Patents and Regulatory Information for VASOCIDIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | VASOCIDIN | prednisolone acetate; sulfacetamide sodium | OINTMENT;OPHTHALMIC | 088791-001 | Oct 5, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Novartis | VASOCIDIN | prednisolone sodium phosphate; sulfacetamide sodium | SOLUTION/DROPS;OPHTHALMIC | 018988-001 | Aug 26, 1988 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
